SCHEMBL294276

SCHEMBL294276

CN(C)c1ncc(-c2cnc3[nH]cc(C(=O)c4cccc(C(N)=O)c4F)c3c2)cn1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 5/20 0.67
▸ AAK1 Q2M2I8 1/20 0.46
▸ AXL P30530 3/20 0.45
▸ CYP2D6 P10635 1/20 0.44
▸ PAK1 Q13153 3/20 0.44
▸ BRAF P15056 3/20 0.43
▸ CDC7 O00311 1/20 0.43
▸ PLK4 O00444 1/20 0.43
▸ CHEK1 O14757 1/20 0.43
▸ AURKA O14965 1/20 0.43
▸ MAPK13 O15264 1/20 0.43
▸ PDPK1 O15530 1/20 0.43
▸ DYRK3 O43781 1/20 0.43
▸ ROCK2 O75116 1/20 0.43
▸ RPS6KA5 O75582 1/20 0.43
▸ PRKD3 O94806 1/20 0.43
▸ PAK4 O96013 1/20 0.43
▸ CHEK2 O96017 1/20 0.43
▸ ABL1 P00519 1/20 0.43
▸ EGFR P00533 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL294277 0.90 CYP2C9 (0.67) CYP2C9AAK1AXLCYP2D6PAK1
SCHEMBL3506669 0.86 AXL (0.58) CYP2C9AAK1AXLPAK1CDC7
SCHEMBL294069 0.86 CYP2C9 (0.69) CYP2C9CYP2D6BRAFEGFRKDR
SCHEMBL2882894 0.86 CYP2D6 (0.59) CYP2C9AAK1AXLCYP2D6PAK1
SCHEMBL2353295 0.84 BRAF (0.53) CYP2C9AAK1AXLPAK1BRAF
SCHEMBL15667416 0.83 CYP2C9 (0.79) CYP2C9CYP2D6BRAFCYP2C19
SCHEMBL3506502 0.83 DYRK1A (0.51) CYP2C9AAK1AXLCDC7PLK4
SCHEMBL3705466 0.82 CYP3A4 (0.52) CYP2C9AAK1AXLCYP2D6PAK1
SCHEMBL2351339 0.82 CYP2C9 (0.48) CYP2C9AAK1AXLPAK1BRAF
SCHEMBL3507600 0.81 AAK1 (0.46) CYP2C9AAK1AXLCYP2D6PAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427462-A1 PYRROLO [2, 3. B]PYRIDINES WHICH INHIBIT RAF PROTEIN KINASE Plexxikon, Inc. (US) 2012-03-14 — — EP claimed
WO-2010129567-A1 PYRROLO [2, 3. B] PYRIDINES WHICH INHIBIT RAF PROTEIN KINASE PLEXXIKON, INC. (US) 2010-11-11 — — WO claimed
US-20100286142-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor PLEXXIKON, INC. 2010-11-11 — — US claimed
US-20120245174-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2012-09-27 — — US disclosed
US-8198273-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2012-06-12 — — US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 — — US disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 — — WO disclosed
US-20100286142-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor PLEXXIKON, INC. 2010-11-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF CYP2C9 2176/4885AAK1 247/4885AXL 470/4885
US-20100286142-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor BRAF, ARAF, RAF1 CYP2C9 2237/4885AAK1 355/4885AXL 97/4885
US-20120245174-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR BRAF, ARAF, RAF1 CYP2C9 2237/4885AAK1 355/4885AXL 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback